NCT04608409 2025-06-29
Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer
University of Kentucky
Phase 1 Completed
Clinical Trials
54 trialsNCT02101905 2024-11-06
Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00963547 2024-06-04
MK-2206-015
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT01199367 2024-04-25
Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer
Kyowa Kirin Co., Ltd.
Phase 1 Terminated
NCT00424164 2024-03-08
LAPATAM
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1 Completed
NCT00251433 2023-03-31
GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer
Novartis
Phase 1 Terminated
NCT00807859 2022-11-08
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Amgen
Phase 1 Completed
NCT02650752 2021-01-26
Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00367471 2020-09-09
Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.
Novartis
Phase 1 Completed
NCT00085020 2020-08-03
GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu
Jonsson Comprehensive Cancer Center
Phase 1 Completed
NCT00543504 2020-06-30
Bevacizumab in Multiple Phase I Combinations
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01434303 2019-05-20
Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only
National Cancer Institute (NCI)
Phase 1 Completed
NCT02073916 2019-04-16
STELA
The Methodist Hospital Research Institute
Phase 1 Completed
NCT00371488 2018-08-31
GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer
GlaxoSmithKline
Phase 1 Completed
NCT00462956 2018-08-31
GW572016 In Patients With Advanced Or Metastatic Breast Cancer
GlaxoSmithKline
Phase 1 Completed
NCT00790816 2018-02-28
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
Novartis
Phase 1 Completed
NCT00536809 2017-12-18
Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer
GlaxoSmithKline
Phase 1 Completed
NCT00148902 2017-12-06
Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)
GlaxoSmithKline
Phase 1 Completed
NCT00258050 2017-12-06
To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients
GlaxoSmithKline
Phase 1 Completed
NCT00158782 2017-11-17
Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients
GlaxoSmithKline
Phase 1 Completed
NCT00169533 2017-11-17
Rollover Study Of Lapatinib In Cancer Patients
GlaxoSmithKline
Phase 1 Completed
NCT00388076 2017-11-17
Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)
GlaxoSmithKline
Phase 1 Completed
NCT00528281 2017-11-17
A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase
GlaxoSmithKline
Phase 1 Completed
NCT00650910 2017-11-17
Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer
GlaxoSmithKline
Phase 1 Completed
NCT00849329 2017-11-14
A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer
GlaxoSmithKline
Phase 1 Completed
NCT00359190 2017-11-13
Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer
GlaxoSmithKline
Phase 1 Completed
NCT00516672 2017-11-13
Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00821054 2017-11-13
A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients
GlaxoSmithKline
Phase 1 Completed
NCT00996762 2017-11-13
A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib
GlaxoSmithKline
Phase 1 Completed
NCT01290354 2017-11-13
Exploratory Lapatinib (Positron Emission Tomography) PET Study in Subjects With Breast Cancer
GlaxoSmithKline
Phase 1 Completed
NCT00662636 2017-03-23
Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery
Mayo Clinic
Phase 1 Completed
NCT01454804 2016-04-13
Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00634088 2016-03-10
Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
R-Pharm
Phase 1 Terminated
NCT01497626 2016-02-17
Lapatinib and Bortezomib in Patients With Advanced Malignancies
Georgetown University
Phase 1 Terminated
NCT00753207 2016-02-15
Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer. ICORG 06-30
Cancer Trials Ireland
Phase 1 Completed
NCT02131506 2016-02-02
CAELYX
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 1 Terminated
NCT01087983 2015-11-11
Lapatinib With Sirolimus or Metformin
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00632489 2015-06-08
LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients
SCRI Development Innovations, LLC
Phase 1 Completed
NCT00682279 2015-04-17
A Phase I Study Of Oral Topotecan And Lapatinib In Subjects With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Withdrawn
NCT00352443 2015-03-06
S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
Phase 1 Completed
NCT00984425 2014-12-02
The Treatment of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors
Istituto Clinico Humanitas
Phase 1 Completed
NCT01238029 2014-11-21
CELAVIE
Sponsor GmbH
Phase 1 Terminated
NCT01245205 2014-10-23
Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00544804 2014-07-02
Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2
University of California, San Francisco
Phase 1 Completed
NCT00623064 2014-07-01
Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1 Completed
NCT00513058 2014-01-14
Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer
UNICANCER
Phase 1 Completed
NCT00316875 2013-11-08
Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer
Northwestern University
Phase 1 Completed
NCT01705340 2013-09-30
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00495872 2012-10-18
Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00614978 2012-09-19
LAPTEM
Jules Bordet Institute
Phase 1 Completed